Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 4/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894637 | 0.89 | PARP1 (0.43) | DGAT1MAPTKMT2ACES2CES1 | |
| SCHEMBL1003390 | 0.84 | CES2 (0.44) | DGAT1KMT2ACES2CES1MAP2K1 | |
| SCHEMBL4047607 | 0.83 | DGAT1 (0.50) | DGAT1MAPTKMT2AKIF11ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29810617 | 0.82 | CES2 (0.43) | DGAT1KMT2ACES2CES1MAP2K1 | |
| SCHEMBL20231916 | 0.81 | CES2 (0.39) | MAPTKMT2ACES2CES1HTT | |
| SCHEMBL30159044 | 0.81 | CES2 (0.39) | MAPTKMT2ACES2CES1HTT | |
| SCHEMBL31140501 | 0.80 | DGAT1 (0.39) | DGAT1KIF11SMN1; SMN2MAP2K1PARP1 | |
| SCHEMBL1871364 | 0.80 | POLB (0.42) | DGAT1MAPTKMT2AHTTALDH1A1 | |
| SCHEMBL26453119 | 0.79 | HTT (0.43) | MAPTKMT2ACES2CES1HTT | |
| SCHEMBL28715121 | 0.77 | CES2 (0.38) | DGAT1MAPTKMT2ACES2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-7098335-B2 | Pyrazolopyrimidine compositions | ICAGEN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050215569-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| US-6833371-B2 | Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell | ICAGEN, INC. | 2004-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215569-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | DGAT1 3657/4885MAPT 3256/4885KMT2A 3544/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | DGAT1 4513/4885MAPT 1035/4885KMT2A 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.